CICC KraneShares CSI China Internet Index ETF (9186)
Market Closed
13 Jan, 01:36
HKEX HKEX Primary HKEX $
6. 62
+0.13
+2.0817%
$
- Market Cap
- P/E Ratio
213.27% Div Yield
50 Volume
- Eps
$ 6.49
Previous Close Want to track 9186 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
9186 closed Friday higher at $6.62, an increase of 2.0817% from Thursday's close, completing a monthly increase of 0% or $6.62. Over the past 12 months, 9186 stock gained 0%.
9186 pays dividends to its shareholders, with the most recent payment made on Feb 06, 2023.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
9186 Chart
CICC KraneShares CSI China Internet Index ETF (9186) FAQ
What is the stock price today?
The current price is $6.62.
On which exchange is it traded?
CICC KraneShares CSI China Internet Index ETF is listed on HKEX.
What is its stock symbol?
The ticker symbol is 9186.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 213.27%.
What is its market cap?
As of today, no market cap data is available.
Has CICC KraneShares CSI China Internet Index ETF ever had a stock split?
No, there has never been a stock split.
CICC KraneShares CSI China Internet Index ETF Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | - CEO | HKEX Exchange | - ISIN |
| Hong Kong Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
E Fund (HK) Solactive Biopharma Select Index ETF is an exchange-traded fund managed by E Fund Management (Hong Kong) Co., Limited. It seeks to provide investment results that closely correspond to the performance of the Solactive Biopharma Select Index, before fees and expenses. The underlying index comprises 100 constituents selected from biopharmaceutical companies listed in the United States and Hong Kong, with up to 30 Hong Kong-listed securities and at least 70 U.S.-listed ones chosen based on market capitalization and liquidity. Constituents are equally weighted within their regions, maintaining a 65% allocation to Hong Kong-listed securities and 35% to U.S.-listed securities, and the index undergoes semi-annual rebalancing. This structure offers diversified exposure to leading biopharmaceutical firms from global innovation hubs including China, the US, Europe, Israel, Switzerland, and Japan, spanning biotechnology, gene therapies, precision medicine, and drug development. The ETF represents a unique blend of established U.S. biopharma giants and emerging Hong Kong biotechnology companies, capturing the globalization of the biopharmaceutical sector driven by aging populations, rising healthcare demands, and ongoing innovations.
Contact Information
Address: 29th Floor
Phone: +852 3929 0988
